Table 1.
Patient characteristics and clinical outcomes.
| Characteristics | Number | % |
|---|---|---|
| Number of Patients | 75 | 100% |
| Median age, years (range) | 61 (38–81) | |
| Gender | ||
| Male | 40 | 53.3% |
| Female | 35 | 46.7% |
| Prior SRS | 6 | 8.0% |
| Number of brain metastases | ||
| <5 | 18 | 24.0% |
| 5–10 | 17 | 22.7% |
| >10 | 40 | 53.3% |
| Leptomeningeal seeding | 45 | 60.0% |
| Histology | ||
| Adenocarcinoma | 61 | 81.3% |
| Squamous cell carcinoma | 4 | 5.3% |
| Non-small cell carcinoma, NOS | 5 | 6.7% |
| Small cell carcinoma | 4 | 5.3% |
| Adenosquamous | 1 | 1.3% |
| GPA | ||
| 0–1.0 | 12 | 16.0% |
| 1.5–2.0 | 33 | 44.0% |
| 2.5–3.0 | 27 | 36.0% |
| 3.5–4.0 | 3 | 4.0% |
| Median follow-up, months (range) | 8.0 (0.7–52.1) | |
| Death | ||
| Yes | 44 | 58.7% |
| No | 31 | 41.3% |
| Intracranial progression after WBRT | ||
| Yes | 37 | 49.3% |
| No | 31 | 41.3% |
| Unknown | 7 | 9.3% |
| Salvage treatment | ||
| Surgery + SRS | 1 | 1.3% |
| SRS | 3 | 4.0% |
| SRT | 2 | 2.7% |
| TKI | 2 | 2.7% |
| WBRT + Bev | 3 | 4.0% |
| Extracranial progression | ||
| Yes | 45 | 60.0% |
| No | 23 | 30.7% |
| Unknown | 7 | 9.3% |
Abbreviations: NOS, not otherwise specified; GPA, graded prognostic assessment; WBRT, whole brain radiotherapy; SRS, stereotactic radiosurgery; SRT, stereotactic radiotherapy; TKI, tyrosine kinase inhibitor; Bev, bevacizumab.